Verano Holdings (VRNO) Share-based Compensation (2021 - 2026)
Verano Holdings' (VRNO) quarterly Share-based Compensation came in at $2.2 million in Q1 2026, down 33.12% year-on-year from $3.3 million in Q1 2025, and down 80.8% on a QoQ basis from $11.5 million in Q4 2025.
Verano Holdings (VRNO) Share-based Compensation (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Share-based Compensation data on file, last reported at $2.2 million in Q1 2026.
- On a quarterly basis, Share-based Compensation fell 33.12% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was $10.4 million, a 36.2% decrease from a year earlier, with the FY2025 full-year figure at $11.5 million, down 32.1% from the prior year.
- Share-based Compensation for Q1 2026 stood at $2.2 million, down from $11.5 million in the prior quarter.
- Over the last five years, Share-based Compensation for VRNO reached as high as $27.1 million in Q1 2022 and fell as low as -$9.0 million in Q4 2023.
- Historically, Share-based Compensation has averaged $4.1 million across 5 years, with a median of $3.9 million in 2024.
- Across the five-year window, Share-based Compensation slumped 285.94% in 2023 and jumped 622.06% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $4.8 million in 2022, then slumped by 285.94% to -$9.0 million in 2023, then surged by 143.57% to $3.9 million in 2024, then soared by 194.12% to $11.5 million in 2025, then plunged by 80.8% to $2.2 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $2.2 million in Q1 2026, $11.5 million in Q4 2025, and -$6.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 11.51 Mn |
| Dec 31, 2025 | 11.51 Mn |
| Sep 30, 2025 | -6.64 Mn |
| Sep 30, 2025 | -6.64 Mn |
| Jun 30, 2025 | 3.34 Mn |
| Jun 30, 2025 | 3.34 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Mar 31, 2025 | 3.30 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Dec 31, 2024 | 3.91 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Sep 30, 2024 | 4.79 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 3.93 Mn |
| Mar 31, 2024 | 3.93 Mn |
| Dec 31, 2023 | -8.98 Mn |
| Dec 31, 2023 | -8.98 Mn |